Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
THE MEDICINES COMPANY v. BIOGEN MA INC.
Case Number:
2:15-cv-07031
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 07, 2018
Biogen, Drugmaker Settle Angiomax Patent Royalties Row
Biogen Inc. has settled a licensing dispute in a New Jersey federal court with a pharmaceutical company over whether the global biotech giant could keep collecting royalties on sales of the blood thinner Angiomax after the patent had expired.
-
September 24, 2015
Biogen Can't Demand Royalties After Patent Expired, Suit Says
A New Jersey-based Biogen licensee slapped the drugmaker with a lawsuit Wednesday for allegedly trying to collect royalties for sales of Biogen's anticoagulant drug after its patent expired, in breach of its contract and in contradiction of U.S. Supreme Court precedent.